← Human Trials & Peer-Reviewed Studies
Arginine counteracts the inhibitory effect of recombinant human insulin-like growth factor I on the somatotroph responsiveness to growth hormone-releasing hormone in humans
Plain-language guide to PMID 11061509 (2000): placebo-controlled randomized controlled trial study of GHRH (Growth Hormone-Releasing Hormone).
Key Facts
- PMID
- 11061509
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2000
- Study type
- Randomized Controlled Trial
- Authors
- Gianotti L et al. (9 authors)
- DOI
- 10.1210/jcem.85.10.6872
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of GHRH (Growth Hormone-Releasing Hormone), published as a randomized controlled trial.
The aim of the present study was to further clarify in humans the mechanisms underlying IGF-I-induced inhibition of somatotroph secretion.
Why It Was Studied
Insulin-like growth factor I (IGF-I) exerts a negative feedback effect on GH secretion via either direct actions at the pituitary level or indirect ones at the hypothalamic level, through stimulation of somatostatin (SS) and/or inhibition of GHRH release.
In fact, recombinant human IGF-I (rhIGF-I) in humans inhibits spontaneous GH secretion as well as the GH response to GHRH and even more to GH/GH-releasing peptides, whose main action is on the hypothalamus, antagonizing SS and enhancing GHRH activity.
Who Took Part
The age groups tagged for this paper are adults, women only.
How the Study Was Run
The researchers set it up as a randomized and placebo-controlled study.
The participants were allocated by chance, so the GHRH (Growth Hormone-Releasing Hormone) group and the comparison group should start out alike.
A placebo (an inactive look-alike) gave the GHRH (Growth Hormone-Releasing Hormone) group a baseline to be compared against.
What Was Measured
Insulin-like growth factor I (IGF-I) exerts a negative feedback effect on GH secretion via either direct actions at the pituitary level or indirect ones at the hypothalamic level, through stimulation of somatostatin (SS) and/or inhibition of GHRH release.
PubMed files the paper under topics including Area Under Curve, Arginine, Blood Glucose, Growth Hormone-Releasing Hormone, Human Growth Hormone, Hypothalamus and Insulin.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of GHRH (Growth Hormone-Releasing Hormone).
The publication is from 2000 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.
Our Notes on the Compound
GHRH (Growth Hormone-Releasing Hormone): The 44-amino-acid hypothalamic hormone that tells the pituitary to release growth hormone; sermorelin and tesamorelin are analogs.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.